A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Patients With Localized Prostate Cancer (MTG-REIC-PC003)
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 24 Oct 2019
Price : $35 *
At a glance
- Drugs Ad5 SGE DKK3 gene therapy-Momotaro (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Momotaro-Gene
- 22 Oct 2019 Planned End Date changed from 1 Jun 2019 to 1 Mar 2020.
- 07 Mar 2019 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 07 Mar 2019 Status changed from recruiting to active, no longer recruiting.